Research Article
Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
Table 3
Results for progression-free survival and overall survival differences in patients with GBM in relation to IDH1 mutation status.
| | Glioblastoma results | | Median [days] (95% Cl) | (Wilcoxon) |
| | Overall survival (OS) | | | | | IDH1 R132H | 20 | 270 (139–400) | 0.024 | | IDH1 wild-type | 24 | 130 (87–172) | | Progression-free survival (PFS) | | | | | IDH1 R132H | 20 | 136 (22–249) | 0.021 | | IDH1 wild-type | 24 | 51 (19–82) |
|
|
